Results 191 to 200 of about 27,419 (207)

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

Modern Rheumatology, 2012
Masayoshi Harigai, Naoki Ishiguro, Tsutomu Takeuchi   +2 more
exaly  

Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation

Chinese Journal of Integrative Medicine, 2014
Zhi-Fei Wang, Xing Liao, Xie Yan-Ming
exaly  

2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.

American Journal of Emergency Medicine, 2003
W. Watson, T. Litovitz, G. C. Rodgers, W. Klein‐Schwartz, J. Youniss, S. R. Rose, D. Borys, M. E. May   +7 more
semanticscholar   +1 more source

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients

Modern Rheumatology, 2014
Naoki Ishiguro, Tsutomu Takeuchi, Hisashi Yamanaka   +2 more
exaly  

Postmarketing surveillance. Is not used to promote products.

BMJ (Clinical research ed.), 1994
openaire   +1 more source

Rivaroxaban postmarketing risk of liver injury

Journal of Hepatology, 2014
Stefan Russmann, Bruno Stieger, Gerd A Kullak-Ublick   +2 more
exaly  

Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

Seminars in Arthritis and Rheumatism, 2015
, , Samy Suissa
exaly  

Monitoring product safety in the postmarketing environment

Therapeutic Advances in Drug Safety, 2013
exaly  

[Publications and postmarketing product surveillance: why and how?].

Annales francaises d'anesthesie et de reanimation, 1998
openaire   +1 more source

Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis

Modern Rheumatology, 2018
Shigeki Momohara, Atsushi Kawakami, Momohara Shigeki   +2 more
exaly